← Back to all trials
Completed
NCT03850782
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension
Conditions: Open-Angle Glaucoma, Ocular Hypertension
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 515
Sponsor: AbbVie
Location: Horizon Eye Specialists & Lasik Centers /ID# 235240 Sun City Arizona
Summary
This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Eligibility Criteria
Inclusion Criteria:
\- Diagnosis of either open angle glaucoma (OAG) (i.e., primary OAG, pseudoexfoliation glaucoma, pigmentary glaucoma) or ocular hypertension requiring intraocular pressure-lowering treatment.
Exclusion Criteria:
* Concurrent or anticipated enrollment in another investigational drug or device study or participation in such a study within 2 months prior to enrolling in this study.
* Previous administration with Bimatoprost SR in the study eye.
Source: ClinicalTrials.gov (NCT03850782). StuddyBuddy aggregates publicly available trial information.